These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26377944)

  • 1. Relationship between soluble intercellular adhesion molecules and attention-deficit/hyperactivity disorder.
    Alaşehirli B; Oguz E; Gokcen C; Erbagcı AB; Orkmez M; Demiryurek AT
    Int J Psychiatry Med; 2015; 50(2):238-47. PubMed ID: 26377944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study.
    Akay AP; Resmi H; Güney SA; Erkuran HÖ; Özyurt G; Sargin E; Topuzoglu A; Tufan AE
    Eur Child Adolesc Psychiatry; 2018 Jan; 27(1):127-135. PubMed ID: 28710695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylphenidate effects on blood serotonin and melatonin levels may help to synchronise biological rhythms in children with ADHD.
    Molina-Carballo A; Naranjo-Gómez A; Uberos J; Justicia-Martínez F; Ruiz-Ramos MJ; Cubero-Millán I; Contreras-Chova F; Augustin-Morales MD; Khaldy-Belkadi H; Muñoz-Hoyos A
    J Psychiatr Res; 2013 Mar; 47(3):377-83. PubMed ID: 23088865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.
    Rubio B; Hernández S; Verche E; Martín R; González-Pérez P
    Atten Defic Hyperact Disord; 2011 Mar; 3(1):13-20. PubMed ID: 21432614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder.
    Sahin S; Yuce M; Alacam H; Karabekiroglu K; Say GN; Salıs O
    Int J Psychiatry Clin Pract; 2014 Oct; 18(4):280-7. PubMed ID: 24994482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
    López-Lerma I; Estrach MT
    J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
    Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
    Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder.
    Gorman EB; Klorman R; Thatcher JE; Borgstedt AD
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):808-16. PubMed ID: 16832317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
    Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK
    Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
    van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
    Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD).
    Amiri A; Torabi Parizi G; Kousha M; Saadat F; Modabbernia MJ; Najafi K; Atrkar Roushan Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Dec; 47():20-4. PubMed ID: 23933054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.